JNC Showcased Viral Vector Purification Products
The company presented new chromatography media for large-particle biopharmaceutical manufacturing at BioProcess International 2026.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe new pharmaceutical manufacturing technologies will lead to better health outcomes?
JNC introduced its latest chromatography portfolio, including the MLP platform, to address purification challenges in large-molecule manufacturing. The technology uses a large-pore bead architecture to improve the separation and concentration of viral vectors.
Why it matters
As biological molecules and particles grow in size, standard purification methods struggle to maintain efficiency. This platform offers a new approach to help manufacturers achieve higher purity and recovery rates for complex viral-based products.
The Cellufine MLP DexS platform utilizes a large-pore bead architecture and dextran sulfate ligands. In testing, this media achieved a 13-fold concentration of inactivated influenza virus while reducing protein impurities by 90.3%.
The players
JNC
JNC is a chemical and material manufacturer that develops specialized chromatography media for biopharmaceutical production.
The details
The Cellufine MLP platform is designed to assist with the separation of full and empty adeno-associated virus particles. By improving target molecule access, the system aims to move beyond conventional column purification into specialized large-particle applications.
Timeline
JNC showcased these chromatography products at BioProcess International 2026 in September 2026.
The Tech Race
The introduction of the MLP platform marks an evolution of the Cellufine chromatography media family to meet the demands of modern viral-vector manufacturing. It positions JNC to capture market share in the growing sector of large-particle biopharmaceutical purification.
This technology aims to streamline the manufacturing of viral-based therapies, which could eventually reduce production costs and bottlenecks in the drug development pipeline. For the industry, this means more efficient purification processes for critical medical treatments.
The takeaway
The move toward large-pore chromatography media highlights the industry focus on adapting hardware to handle increasingly complex biological molecules. Manufacturers should monitor these performance metrics as they evaluate new solutions for improving their own purification efficiency.
Further reading
For more information on the latest innovations in pharmaceutical production, visit the Biotech section.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Do you believe new pharmaceutical manufacturing technologies will lead to better health outcomes?
